Sanara MedTech Inc develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States.
infoSanara MedTech is a small cap stock with a total market cap of 324.51M.
infoThey trade on the NASDAQ and had their IPO 29 years and 4 months ago.
infoSanara MedTech currently employs 101 people.
infoAs of Wednesday, Aug 23 2023, Sanara MedTech’s share price is $38.08.
News Relating to Sanara MedTech
Seeking Alpha
Sanara Medtech, Inc. (SMTI) Q2 2023 Earnings Call Transcript
Tuesday Aug 15 2023 at 13:51
Sanara Medtech, Inc. (NASDAQ:SMTI ) Q2 2023 Earnings Conference Call August 15, 2023 9:00 AM ET Company Participants Callon Nichols – VP, Corporate Operations Ron Nixon – Executive Chairman Zach Fleming – CEO Mike McNeil – CFO Conference Call Participants Ross Osborn – Cantor Fitzgerald Ian Cassel – MicroCap Club Operator Greetings. Welcome to the Sanara MedTech Inc. Second Quarter 2023 Results and Business Update Conference Call.
GlobeNewsWire
Sanara MedTech Inc. Announces Second Quarter Earnings Release and Conference Call Dates
Tuesday Aug 01 2023 at 16:05
FORT WORTH, TX, Aug. 01, 2023 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today details for the release of its results for the quarter ended June 30, 2023.
Zacks Investment Research
Down -14.23% in 4 Weeks, Here’s Why Sanara MedTech Inc. (SMTI) Looks Ripe for a Turnaround
Wednesday May 24 2023 at 10:42
The heavy selling pressure might have exhausted for Sanara MedTech Inc. (SMTI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
GlobeNewsWire
Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates
Wednesday May 03 2023 at 09:15
FORT WORTH, TX, May 03, 2023 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today details for the release of its results for the quarter ended March 31, 2023.
GlobeNewsWire
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Earnings Release and Conference Call Dates
Monday Mar 06 2023 at 09:15
FORT WORTH, TX, March 06, 2023 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin care markets, announced today details for the release of its results for the quarter and year ended December 31, 2022.
Zacks Investment Research
What Makes Sanara MedTech Inc. (SMTI) a Good Fit for ‘Trend Investing’
Friday Feb 03 2023 at 10:32
If you are looking for stocks that are well positioned to maintain their recent uptrend, Sanara MedTech Inc. (SMTI) could be a great choice. It is one of the several stocks that passed through our “Recent Price Strength” screen.
Seeking Alpha
Sanara MedTech: A High Growth Micro Cap Disrupting The Wound And Skin Care Space
Friday Dec 09 2022 at 12:22
A micro cap health tech company following a path to large cap potential. A management team with vision, ownership, operational expertise, domain knowledge and that trust each other.
Seeking Alpha
Sanara MedTech: Triple-Digit Revenue Upside In Q3, Expanding Footprint, Reaffirm Buy
Thursday Dec 08 2022 at 04:24
Tremendous growth during the quarter with 124% revenue upside from this time last year. Continues to expand its footprint and sales channels, pushing towards its market goals.
Seeking Alpha
Sanara Medtech, Inc. (SMTI) Q3 2022 Earnings Call Transcript
Tuesday Nov 15 2022 at 13:59
Sanara Medtech, Inc. (NASDAQ:SMTI ) Q3 2022 Earnings Conference Call November 15, 2022 9:00 AM ET Company Participants Callon Nichols – Director, IR Ronald Nixon – Executive Chairman Zachary Fleming – CEO Michael McNeil – CFO & Corporate Secretary Conference Call Participants Christopher Plahm – Tall Pines Capital Ian Cassel – MicroCapClub Operator Good day, ladies and gentlemen, and welcome to the Sanara MedTech Inc. Q3 2022 Earnings and Business Update. [Operator Instructions].
GlobeNewsWire
Sanara MedTech Inc. Announces Third Quarter 2022 Earnings Release and Conference Call Dates
Tuesday Nov 01 2022 at 09:15
FORT WORTH, TX, Nov. 01, 2022 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the quarter ended September 30, 2022.
GlobeNewsWire
Sanara MedTech to Present at the Virtual MicroCap Leadership Summit
Tuesday Sep 06 2022 at 09:15
FORT WORTH, TX, Sept. 06, 2022 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it has been selected to present at the 7th annual MicroCap Leadership Summit on Friday, September 16th, 2022. The MicroCap Leadership Summit is a two-day virtual event hosted by MicroCapClub.
Seeking Alpha
Sanara MedTech Inc. (SMTI) CEO Zachary Fleming on Q2 2022 Results – Earnings Call Transcript
Tuesday Aug 16 2022 at 13:28
Sanara MedTech Inc. (NASDAQ:SMTI ) Q2 2022 Earnings Conference Call August 16, 2022 9:00 AM ET Company Participants Callon Nichols – Director of IR Ron Nixon – Executive Chairman Zachary Fleming – CEO Michael McNeil – CFO Conference Call Participants Ross Osborn – Cantor Fitzgerald Ian Cassel – IFCM Operator Good morning, ladies and gentlemen, and welcome to the Sanara MedTech Inc. Second Quarter 2022 Earnings and Business Update. At this time, all participants have been placed on a listen-only mode and the floor will be opened for questions and comments after the presentation.
GlobeNewsWire
Sanara MedTech Inc. Announces Second Quarter 2022 Earnings Release and Conference Call Dates
Wednesday Aug 03 2022 at 09:15
FORT WORTH, TX, Aug. 03, 2022 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the second quarter ended June 30, 2022.
Seeking Alpha
Sanara MedTech Inc. (SMTI) CEO Zach Fleming on Q1 2022 Results – Earnings Call Transcript
Tuesday May 17 2022 at 10:33
Sanara MedTech Inc. (NASDAQ:SMTI ) Q1 2022 Earnings Conference Call May 17, 2022 9:00 AM ET Company Participants Callon Nichols – Director, Investor Relations Ron Nixon – Executive Chairman Zach Fleming – Chief Executive Officer Mike McNeil – Chief Financial Officer Conference Call Participants Ian Cassel – IFCM Operator Good morning, ladies and gentlemen, and welcome to the Sanara MedTech Inc. First Quarter 2022 Results and Business Update Conference Call. At this time, all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.
GlobeNewsWire
Sanara MedTech Inc. Announces First Quarter 2022 Earnings Release and Conference Call Dates
Monday May 02 2022 at 09:15
FORT WORTH, TX, May 02, 2022 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the first quarter ended March 31, 2022.
Seeking Alpha
Sanara MedTech Inc. (SMTI) CEO Zach Fleming on Q4 2021 Results – Earnings Call Transcript
Thursday Mar 31 2022 at 11:51
Sanara MedTech Inc. (SMTI) CEO Zach Fleming on Q4 2021 Results – Earnings Call Transcript
GlobeNewsWire
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2021 Earnings Release and Conference Call Dates
Monday Mar 14 2022 at 09:15
FORT WORTH, TX, March 14, 2022 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the fourth quarter and full year ended December 31, 2021.
Seeking Alpha
Sanara MedTech: Technology For Faster Healing Wounds
Tuesday Dec 07 2021 at 20:16
Sanara MedTech develops and sells medical products for post-surgery or chronic wounds. Their products are gaining traction, and revenue is growing rapidly (54.76% YoY revenue growth in the most recent quarter).
Seeking Alpha
Sanara MedTech Inc. (SMTI) Management on Q3 2021 Results – Earnings Call Transcript
Monday Nov 15 2021 at 14:16
Sanara MedTech Inc. (SMTI) Management on Q3 2021 Results – Earnings Call Transcript
Seeking Alpha
A Future Wound Care Compounder With Massive Upside Optionality – Sanara MedTech
Thursday Nov 11 2021 at 18:53
Sanara MedTech is undervalued based on the explosive growth in its primary product, Cellerate.
Accesswire
Sanara MedTech Inc. Announces Third Quarter 2021 Earnings Release and Conference Call Dates
Thursday Oct 28 2021 at 09:15
FORT WORTH, TX / ACCESSWIRE / October 28, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today details for the release of its results for the third quarter ended September 30, 2021. Sanara plans to issue its earnings release after the market closes on Friday, November 12, 2021, and will host a conference call on Monday, November 15, 2021, at 9:00 a.m.
Accesswire
Sanara MedTech to Present at the 2021 Cantor Virtual Global Healthcare Conference
Wednesday Sep 22 2021 at 09:15
FORT WORTH, TX / ACCESSWIRE / September 22, 2021 / Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that the Company is scheduled to present virtually at the 2021 Cantor Virtual Global Healthcare Conference. Sanara’s presentation will be given on Wednesday, September 29, 2021 at 9:20 a.m.
Accesswire
Sanara MedTech to Present at the Virtual MicroCap Leadership Summit
Thursday Aug 26 2021 at 09:15
FORT WORTH, TX / ACCESSWIRE / August 26, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today it has been selected to present at the 6th annual MicroCap Leadership Summit on Friday, September 24, 2021. The MicroCap Leadership Summit is a two-day virtual event hosted by MicroCapClub.
Seeking Alpha
Sanara MedTech Inc. (SMTI) Management on Q2 2021 Results – Earnings Call Transcript
Tuesday Aug 17 2021 at 17:25
Sanara MedTech Inc. (SMTI) Management on Q2 2021 Results – Earnings Call Transcript
Accesswire
Sanara MedTech Inc. Announces Second Quarter 2021 Results and Business Update
Monday Aug 16 2021 at 16:15
FORT WORTH, TX / ACCESSWIRE / August 16, 2021 / Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quarter ended June 30, 2021.
Accesswire
Sanara MedTech Inc. Announces Second Quarter 2021 Earnings Release and Conference Call Dates
Monday Aug 02 2021 at 09:15
FORT WORTH, TX / ACCESSWIRE / August 2, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today details for the release of its results for the second quarter ended June 30, 2021. Sanara plans to issue its earnings release after the market closes on Monday, August 16, 2021, and will host a conference call on Tuesday, August 17, 2021, at 9:00 a.m.
Accesswire
Sanara MedTech Inc. Announces the Purchase of Certain Assets from Rochal Industries, LLC
Monday Jul 19 2021 at 09:15
FORT WORTH, TX / ACCESSWIRE / July 19, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today the acquisition of certain assets of Rochal Industries, LLC (“Rochal”). Ron Nixon, Sanara’s Executive Chairman, stated, “As part of our comprehensive wound and skin strategy, Sanara is committed to commercializing innovative products that improve outcomes at a lower overall cost.
Accesswire
Sanara MedTech Inc. Announces Exclusive Partnership with Pixalere Healthcare Inc. to Advance its Comprehensive Wound and Skin Care Strategy
Friday Jun 04 2021 at 09:15
FORT WORTH, TX / ACCESSWIRE / June 4, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today that it has closed an exclusive partnership with Pixalere Healthcare Inc. (“Pixalere”). Ron Nixon, Sanara’s Executive Chairman, stated, “Our goal at Sanara MedTech is to offer comprehensive wound and skin care solutions across all care settings.
Accesswire
Sanara MedTech Inc. Announces First Quarter 2021 Results and Business Update
Monday May 17 2021 at 09:15
FORT WORTH, TX / ACCESSWIRE / May 17, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quarter ended March 31, 2021. Ron Nixon, Sanara’s Executive Chairman, stated, “The first quarter of 2021 was another record quarter for Sanara.
Seeking Alpha
Neil Cataldi From Blueprint Discusses Sanara MedTech
Monday May 03 2021 at 09:41
SMTI’s stock has fallen in the wake of a recent equity raise. Neil Cataldi from Blueprint Capital discusses what he thinks the market is missing.
Sanara MedTech Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Sanara MedTech’s Altman Z-score is 11.29 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
Sanara MedTech Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Sanara MedTech.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Sanara MedTech’s Income Quality of 0.35 is lower than its Industry Group of 0.68 (-48.5% lower)
Sanara MedTech’s Income Quality of 0.35 is lower than its Major Industry Group of 0.71 (-50.7% lower)
Sanara MedTech’s Income Quality of 0.35 is lower than its Sector of 0.75 (-53.3% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Sanara MedTech’s Current Ratio of 1.84 is lower than its Industry Group of 3.36 (-45.2% lower)
Sanara MedTech’s Current Ratio of 1.84 is lower than its Major Industry Group of 3.13 (-41.2% lower)
Sanara MedTech’s Current Ratio of 1.84 is lower than its Sector of 2.6 (-29.2% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-19.58 & -1.02)
Cannot compare a negative PE Ratio (-19.58 & -0.58)
Cannot compare a negative PE Ratio (-19.58 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Sanara MedTech’s PB Ratio of 14.24 is greater than its Industry Group of 1.9 (649.5% greater)
Sanara MedTech’s PB Ratio of 14.24 is greater than its Major Industry Group of 1.93 (637.8% greater)
Sanara MedTech’s PB Ratio of 14.24 is greater than its Sector of 1.62 (779.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Sanara MedTech’s ROE of -0.73 is lower than its Industry Group of -0.26 (-180.8% lower)
Sanara MedTech’s ROE of -0.73 is lower than its Major Industry Group of -0.09 (-711.1% lower)
Sanara MedTech’s ROE of -0.73 is lower than its Sector of -0.03 (-2333.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Sanara MedTech’s ROCE of -0.31 is lower than its Industry Group of -0.27 (-14.8% lower)
Sanara MedTech’s ROCE of -0.31 is lower than its Major Industry Group of -0.14 (-121.4% lower)
Sanara MedTech’s ROCE of -0.31 is lower than its Sector of -0.04 (-675.0% lower)
Derived from SEC.GOV filing dataopen_in_new